Get started

PFE

PFE Pfizer to All Time HighIf you haven`t bought at my first call, when PFE was $40: Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five. Still low PE Ratio (TTM) 15.42 Decent Forward Dividend & Yield 1.56 (2.89%) The stock jumped also on the promise of its antiviral pill! For me is a Buy even at this level!
NYSE:PFELong
by TopgOptions
1
Pfeizer. Flat again. PFEThis is beginning to sound like a broken record. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NYSE:PFEShort
by Rykin_Capital
ascending channel, gains after earnings, short-time bullishNot financial advice! We can clearly see the ascending channel of this stock. Even though the stock is running for quite some time now, I don't think it will actually stop before we see $54,XX. After last earnings the stock gained about 20% and reached the top of channel after 14 trading days. From my point of view, since the last earnings reported were even better and the Covid-medication is on the way, there is no doubt that it will touch the top of channel again within a few days. If it does, it magically gained about 20% within 14 trading days after earnings. Watch the last high closely, as PFE may get rejected there. Not financial advice!
NYSE:PFE
by robvanhoven
$EXPE PEG and Cup With Handle BreakoutI've put relevant notations on the chart. I'm putting this on my action list for next week. Many ways to play this one. If it opens in the upper wick that's strong. If that's the case I may go long with a stop below the day low or open. I may wait for a pullback but look for the gap to hold. It could also flag here for a few days or weeks. Either way this should be on your watch list. Ideas, not investing / trading advice. As a side note there are quite few gappers this week worthy of a watch list such as $GDYN, $SYNA, $LYV, $PFE, $GT, $TGI and $BA which I've posted an idea on.This list is only a few, it's been a great week for many stocks breaking out.
NASDAQ:EXPELong
by jaxdog
PFE is bullish with Aspen Trading Support & Resistance LevelsPFE has bounced up from support @ 41.5 using Aspen Trading Support & Resistance Levels. Next target is 49.5 and a move above this level can lead to further upside. More tailwinds, it is above 50 & 200 moving averages and PFE typically displays seasonal strength this time of year. Please like, share and follow if you agree with the analysis. Note - Aspen Trading S/R levels are invite only. They can be accessed through my profile information. Disclaimer: This analysis is for information purpose only and does not constitute any investment advice.
PLong
by tradingswift
Pfizer | Fundamental Analysis | Must Read ⚡️Pfizer has grown an authority at being first. The pharmaceutical behemoth was the pioneer to introduce a coronavirus vaccine a year ago. Since then, it has had several other successes: bringing the COVID-19 booster to market, getting approval for its vaccine for adolescents, and most recently getting approval for a vaccine for children. This has been followed by a lot of revenue. Moreover, the company recently raised its revenue forecast for coronavirus vaccines this year to $36 billion. Pfizer also raised its total revenue forecast to at least $81 billion as demand for the company's other drugs grows as well. At the same time, the company's stock is up about 18% this year. So now the big question is: Is it too late to buy Pfizer stock? First, let's look at Pfizer's performance now and what may lie ahead. Last week, Pfizer reported a 134 percent increase in third-quarter revenue to $24.1 billion. That includes sales of the coronavirus vaccine. It's impossible to say exactly how much sales of this drug will grow after the pandemic, but it looks like sales of the vaccine could remain at the "best-seller" level for a long time to come. Experts say the virus will persist into the future, so we need protection - and that means regular vaccinations. As recent studies have shown, immunity declines a few months after the initial vaccination. Let's take a look at what Pfizer itself says about future vaccine revenues. During its earnings report, the company said that some projections of vaccine revenue for 2022 look "very high," and offered more moderate projections. Pfizer projected vaccine revenue for 2022 at $29 billion, based on the delivery of 1.7 billion doses. That's still a pretty impressive level. And that figure could be higher. Pfizer can produce 4 billion doses, and the company is still negotiating with governments. Meanwhile, two elements are helping Pfizer continue to gain market share for coronavirus vaccines: the booster and the use of the vaccine in children and adolescents. The company is just getting started in these areas, so they clearly can help boost orders as countries plan the number of doses needed for next year and beyond. The competitor's Moderna vaccine is not yet available for teens and children in the U.S. This means that Pfizer has an opportunity to dominate these age groups. At the same time, Pfizer is moving closer to conquering another COVID-19 market: the treatment market. The company's investigational coronavirus pill is currently in late-stage clinical trials. The company says trial data could be available as early as this quarter. The potential pill could be a game-changer because it could be prescribed immediately after a person is diagnosed with COVID-19 and could be taken at home. Competing company Merck, however, maybe first on the market with a potential pill treatment. It has already requested approval for its drug. But given the need for such a drug, both companies could generate billions of dollars in revenue in this area. Analysts talk a lot about coronavirus. But the reality is that Pfizer has many other sources of revenue today - and potential in the future. This means that Pfizer can continue to thrive even if sales of the COVID-19 vaccine stall or decline. The drivers of today's revenue are seven other drugs. Two of them, the blood-thinning drug Eliquis and the cardiovascular drugs Vyndaqel/Vyndamax, posted double-digit revenue growth in the third quarter. Pfizer has 94 programs in development. Of these, 29 are in phase 3 trials. This is cause for optimism about the company's ability to make up for possible declines in sales of its older drugs. As mentioned earlier, Pfizer stock is up this year, but the stock is only trading at 10 times earnings guidance. This is a bargain, given Pfizer's near- and long-term growth prospects. Pfizer's growing return on invested capital and free cash flow are two more reasons to be optimistic about the stock. Pfizer is also a good bet for income-seeking investors. The company just paid its 331st consecutive quarterly dividend. So, is it too late to buy Pfizer? Not if you're a long-term investor. Pfizer stock hasn't soared as fast as stocks of biotech companies involved in the fight against the coronavirus. And they're unlikely to do so in the future. But Pfizer has plenty of fuel for incremental earnings growth in the future - and that should lead to sustained, long-term stock price gains.
NYSE:PFELong
by FOREXN1
7
Pfizer and Ghislaine and JeffHavin a look is all. Such a move in PFE, worth reflecting on what Big Pharma really is. Do you know why USA is only country that allows TV commercials of Big Pharma? Any other countries? Why so many connections to FDA? Why so many connections to the Israelis and regular attendees at Bilderberg. People will dismiss these connections as tinfoil then drool over a vaguely worded FED statement, trusting the bots to decipher bias. People will place earnings trades based on economic data. And these larger Bilderbeg and WEF groups are looking at data from sky high macro view. From a practical perspective, some of them think they are just solving problems.
NYSE:PFEShort
by allthemoneys
Novavax ShortPfizer's monopoly is very strong on the Covid-19 vaccines . They are spending millions hiding their side effects and creating hurdles for their competitors at the regulatory agencies SUCCESSFULLY . It maybe that Novavax has one the best products out there but that simply does not matter at this point , we know how powerful big pharma can be and Novavax's lateness to the game will not serve them well here . The biggest dangers to NVAX are now the regulatory agencies taking long/asking for additional info and the COVID-19 Antiviral drug news ( Merck's pill approval will be this months and Pfizer may come out with their Phase III study result any moment now). Both are very likely . NVAX will likely reject braking $200 TODAY. $195 -$200 will be a great entry point for a opening a short position on this . RISK /REWARD RATIO VERY LUCRATIVE .
NASDAQ:NVAXShort
by Bobpnmicro
4
TARGET HIT $PFR 9.05% in 14 days TARGET HIT $PFR 9.05% in 14 days Wooo hoooo…. Great game!!! Definitely room for this to go higher... —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your own due diligence. If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can. Have fun, y’all!! (\_/) ( •_•) / >🚀
NYSE:PFE
by SPYder_QQQueen_Trading
PFE Pfizer on the 8hr Popping the cloud.So I have been blending a lot of my styles together and recently i have had a lot of success with the 4 hr Chart using the cloud. When I remembered that I use to trade multiple timeframes because they repeat the same pattern on each time frame. So if that was the case I should be able to find a 8 hour chart where PFE is popping the cloud since the 4hr had already popped the cloud days ago. So I pulled up the 8hr and it was sitting in the cloud about to pop. It just popped the cloud and now is coming back down to find support before breaking out to go for a new high. Resistance is at 43.70. Once it gathers up enough shares to control the float it will clear this area. The white line is actually the copy of the same move on the 4hr chart. I copied and pasted it on the 8 hr so I can get the exact same path the 4hr took on the 8hr chart. by iCantw84it 11.01.2021
NYSE:PFELong
by iCantw84it
3
$PFE - Key Levels and Analysis$PFE - Key Levels and Analysis So it looks like It might be time to start a position in PFE… Target 45.92, or double position at 38.30 @Smartdaytrading I’m not sure if you saw this since the last post, its right at that projected buy level. This is definitely on my radar for tomorrow. —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your due diligence. If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can. Have fun, y’all!!
NYSE:PFELong
by SPYder_QQQueen_Trading
2
Pfizer could be a low risk play at this levels..!Pizer reacted to 200 EMA as well as one of the most important support levels(green line) and just gets out of the downward regression channel. I think it is highly likely we see higher prices in the coming days. My yesterday analysis: (it was not published publicly): Entry: 41.55 Stop loss:40.92 Reward/Risk:5.03 Target range: 44.55 Time Frame: 2Wks Possible gain: 7.635 Possible loss: 1.52% Position size: 5 % of trading capital This is a trade opportunity before the next earning call DISCLAIMER I’m not a certified financial planner/advisor nor a certified financial analyst nor an economist nor a CPA nor an accountant nor a lawyer. I’m not a finance professional through formal education. The contents on this site are for informational purposes only and do not constitute financial, accounting, or legal advice. I can’t promise that the information shared on my posts is appropriate for you or anyone else. By using this site, you agree to hold me harmless from any ramifications, financial or otherwise, that occur to you as a result of acting on information found on this site.
NYSE:PFELong
by Moshkelgosha
4